Schonck, Willemijn A. M.
Stroes, Erik S. G.
Hovingh, G. Kees
Reeskamp, Laurens F. http://orcid.org/0000-0002-8043-951X
Article History
Accepted: 8 January 2024
First Online: 25 January 2024
Declarations
:
: The preparation of this review was not supported by any external funding.
: W.A.M.S. reports no conflict of interests. E.S.G.S. has received fees paid to his institution from Amgen, Akcea, Athera, Sanofi-Regeneron, Esperion, Novo Nordisk, Lily, and Novartis. L.F.R. is cofounder of Lipid Tools and reports speaker fees from Ultragenyx, Daiichi Sankyo, and Novartis. G.K.H. reports research grants from the Klinkerpad fonds, and part-time employment at Novo Nordisk A/S, Denmark since April 2019. G.K.H. is shareholder of Novo Nordisk.
: Not applicable.
: Not applicable.
: Not applicable.
: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: WAMS: investigation, visualization, and writing—original draft. ESGS: supervision and writing—review and editing. GKH: supervision and writing—review and editing. LFR: supervision and writing—review and editing.